EMA Authorised: Incresync (alogliptin;pioglitazone) — Takeda Pharma A/S

View source ↗

Summary

The EMA authorised Incresync, a combination product of alogliptin and pioglitazone, for type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Incresync (alogliptin; pioglitazone)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Takeda Pharma A/S. Decision date: 07/09/2022